Home
Investors
Annual Review 2006
2006 performance highlights

2006 performance highlights

How we did in 2006

Financial performance

Optimising the performance of key products

95.5p

Earnings per share

19% growth over 2005 at constant exchange rates (CER)

£2.6bn

Free cash flow

44% decrease compared to 2005, due mainly to a tax settlement of £1.8 billion in the US

£3.3bn

Sales of Seretide/Advair

11% growth over 2005 at CER

£1.6bn

Sales of Avandia group of products

25% growth over 2005 at CER

Delivering our product pipeline for patients

Cervarix

Our vaccine to prevent cervical cancer

European approval is expected in 2007 and a US filing by April 2007. Cervarix offers up to 100 per cent protection against the two most common cancer-causing HPV types, the virus which causes cervical cancer

H5N1

Our pandemic flu vaccine

Was filed for regulatory approval in Europe in January 2007

94

New chemical entities in clinical development at the end of February 2007

Comprises 15 in phase III/ registration, 46 in phase II and 33 in phase I

23

Vaccines in clinical development at the end of February 2007

Comprises 12 in phase III/ registration, 8 in phase II and 3 in phase I

31

Major product opportunities now in phase III development or registration

Comprises 13 NCEs, 6 vaccines and 12 PLEs

Tykerb

Our new medicine for advanced breast cancer

Was filed for approval in the US in September and Europe in October 2006, with further filings made in markets around the world in the last few months. Seven phase III studies are currently in progress to investigate the effect of Tykerb in patients with breast cancer and we expect to file for additional indications as results from these studies become available

Improving access to medicines

Being the best place
for the best people to do their best work

206m

Tablets of Combivir and Epivir HIV/AIDS medicines supplied to developing countries

This includes 120 million tablets supplied by generic manufacturers licensed by GSK

63% increase over 2005

£302m

Value of community investment in 2006

We make donations of money, medicines, vaccines, time and equipment to support good causes

Equivalent to 3.9% of profit before tax

1st

Managers rated their overall satisfaction with GSK higher than any of our peers in the benchmark group of major companies

Result from our biennial Global Leadership Opinion Survey 2006

91%

Of managers believe colleagues show commitment to performance with integrity